|
🐜
|
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.
15 auth.
D. Fliser,
B. Kollerits,
U. Neyer,
D. Ankerst,
K. Lhotta,
A. Lingenhel,
E. Ritz,
F. Kronenberg,
E. Kuen,
P. König,
...
G. Kraatz,
JohannesF. E. Mann,
G. Müller,
H. Köhler,
P. Riegler
|
9 |
2007 |
9
🐜
|
|
🐜
|
Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure.
14 auth.
F. Kronenberg,
E. Kuen,
E. Ritz,
R. Junker,
P. König,
G. Kraatz,
K. Lhotta,
JohannesF. E. Mann,
G. Müller,
U. Neyer,
...
Werner Riegel,
P. Riegler,
V. Schwenger,
A. Eckardstein
|
7 |
2000 |
7
🐜
|
|
🐜
|
Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis.
10 auth.
F. Kronenberg,
P. König,
U. Neyer,
M. Auinger,
Andreas Pribasnig,
U. Lang,
...
J. Reitinger,
G. Pinter,
G. Utermann,
H. Dieplinger
|
7 |
1995 |
7
🐜
|
|
🐬
|
Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study
Gisela Sturm,
B. Kollerits,
U. Neyer,
E. Ritz,
F. Kronenberg
|
7 |
2008 |
7
🐬
|
|
🐜
|
The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up.
9 auth.
F. Kronenberg,
U. Neyer,
K. Lhotta,
E. Trenkwalder,
M. Auinger,
Andreas Pribasnig,
...
Thomas Meisl,
P. König,
H. Dieplinger
|
7 |
1999 |
7
🐜
|
|
🐬
|
Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin.
G. Weiss,
E. Meusburger,
Gudrun Radacher,
K. Garimorth,
U. Neyer,
G. Mayer
|
6 |
2003 |
6
🐬
|
|
🐜
|
Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients.
9 auth.
F. Kronenberg,
A. Lingenhel,
U. Neyer,
K. Lhotta,
P. König,
M. Auinger,
...
M. Wiesholzer,
H. Andersson,
H. Dieplinger
|
6 |
2003 |
6
🐜
|
|
🐜
|
Interferon treatment for chronic hepatitis C virus infection in uremic patients.
9 auth.
Paul Koenig,
Wolfgang Vogel,
F. Umlauft,
Katharina Weyrer,
R. Prommegger,
Karl Lhotta,
...
U. Neyer,
Hans Krister Stummvoll,
K. Gruenewald
|
6 |
1994 |
6
🐜
|
|
🐜
|
Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease.
9 auth.
F. Kronenberg,
H. Kathrein,
P. Konig,
U. Neyer,
W. Sturm,
K. Lhotta,
...
Ernst Grochenig,
G. Utermann,
H. Dieplinger
|
6 |
1994 |
6
🐜
|
|
🐬
|
Vitamin D deficiency is associated with poor response to active hepatitis B immunisation in patients with chronic kidney disease.
E. Zitt,
H. Sprenger-Mähr,
F. Knoll,
U. Neyer,
K. Lhotta
|
6 |
2012 |
6
🐬
|
|
🐜
|
Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study.
11 auth.
Eva Boes,
D. Fliser,
E. Ritz,
P. König,
K. Lhotta,
JohannesF. E. Mann,
...
G. Müller,
U. Neyer,
W. Riegel,
P. Riegler,
F. Kronenberg
|
6 |
2006 |
6
🐜
|
